Clinical effects and in vitro studies of trifluorothymidine combined with interferon-α for treatment of drug-resistant and -sensitive herpes simplex virus infections

C. J. Birch, D. P. Tyssen, G. Tachedjian, R. Doherty, K. Hayes, A. Mijch, C. R. Lucas

Research output: Contribution to journalArticleResearchpeer-review

60 Citations (Scopus)


Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-α. Complete healing of lesions occurred in 1 patient; a second had significant regression of the infected area. In the third, the lesion was stabilized twice after application of the preparation and reduced in size after a subsequent treatment. In vitro studies confirmed that isolates from these patients were acyclovir- or acyclovir/foscarnet- resistant. In addition, they revealed strong synergy between TFT and interferon-α for these isolates and for strains with wild-type drug sensitivity profiles. Topical TFT/interferon-α may be of benefit in the therapy of mucocutaneous HSV infections, especially when they are resistant to treatment with systemic antiviral agents.

Original languageEnglish
Pages (from-to)108-112
Number of pages5
JournalThe Journal of Infectious Diseases
Issue number1
Publication statusPublished - 1 Jan 1992
Externally publishedYes

Cite this